Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03319459
Title FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Fate Therapeutics

hepatocellular carcinoma

Her2-receptor positive breast cancer

head and neck squamous cell carcinoma

renal cell carcinoma

stomach cancer

colorectal cancer

Advanced Solid Tumor



FATE-NK100 + Trastuzumab

Cetuximab + FATE-NK100

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.